New boxed warnings are being added to the patient information leaflets (PIL) of montelukast due to neuropsychiatric reactions as a result of MHRA review
More prominent warnings are to be added to the leaflet that is provided with every pack of montelukast (Singulair) in the UK, reminding patients and healthcare professionals that they should be alert to serious behaviour and mood-related changes (neuropsychiatric reactions) associated with the treatment, Healthcare professionals must make patients and their caregivers aware of this information. Patients should immediately speak to their prescriber or seek urgent medical attention if neuropsychiatric reactions occur. The Medicines and Healthcare products Regulatory Agency (MHRA) issued this guidance today through its Drug Safety Update (DSU).
Neuropsychiatric reactions have been reported in people taking montelukast, an oral add-on therapy for the treatment of asthma in patients aged 6 months and older. The most frequently reported neuropsychiatric reactions among all age groups are sleep disorders, hallucinations, anxiety and depression, and changes in behaviour and mood, While the benefits of montelukast continue to outweigh the risks for most patients for the management of asthma, the MHRA has continued to receive Yellow Card reports from patients and caregivers since our last Drug Safety Update article in 2019, including some raising concerns about a potential lack of awareness of the risk of neuropsychiatric reactions, The MHRA has conducted a thorough review of the evidence which confirmed that while the risk of neuropsychiatric reactions with montelukast remains unchanged, Yellow Card reports have indicated this risk is potentially not well known by healthcare professionals, patients and their caregivers.
In response, new boxed warnings are being added to the patient information leaflets (PIL) which are supplied with every montelukast product in the UK to make these risks more prominent to the reader. These reactions are typically uncommon, and more serious reactions such as hallucinations, disorientation and suicidal thoughts and actions are very rare.
Dr Alison Cave, MHRA Chief Safety Officer, said:
Patient safety is our top priority. Throughout our review, we have listened to patient representatives and taken independent clinical advice from paediatricians, specialists in mental and respiratory health and experts from the Commission on Human Medicine’s Expert Advisory Groups.
We have now taken regulatory action to update the leaflet included in all montelukast medicine packs in the UK with prominent warnings and advice about the risk of serious behaviour and mood-related changes. Healthcare professionals should inform patients of these potential side effects. Patients and carers should immediately speak to their prescriber or seek urgent medical attention if the patient experiences any neuropsychiatric symptoms while using montelukast.
We keep all medicines under continuous review to ensure that the benefits outweigh the risks for most patients. We encourage patients, healthcare professionals and carers to report any suspected side effects with montelukast to the Yellow Card scheme.
For the full article information: Outcome of MHRA review of neuropsychiatric reactions with montelukast - GOV.UK (www.gov.uk)
